Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy

final results of the randomized GO-FORTH trial

Yoshiya Tanaka, Masayoshi Harigai, Tsutomu Takeuchi, Hisashi Yamanaka, Naoki Ishiguro, Kazuhiko Yamamoto, Nobuyuki Miyasaka, Takao Koike, Daniel Baker, Yutaka Ishii, Toru Yoshinari

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: To evaluate the safety and efficacy of golimumab + methotrexate (MTX) in Japanese patients with active rheumatoid arthritis (RA). Methods: Japanese patients with active RA despite MTX were randomized to placebo + MTX (Group 1, n = 88), golimumab 50 mg + MTX (Group 2, n = 86), or golimumab 100 mg + MTX (Group 3, n = 87). Patients with 

Original languageEnglish
Pages (from-to)1-10
Number of pages10
JournalModern Rheumatology
DOIs
Publication statusAccepted/In press - 2015 Dec 22

Fingerprint

Methotrexate
Rheumatoid Arthritis
Safety
Therapeutics
Placebos
golimumab

Keywords

  • Anti-tumor necrosis factor
  • Asian
  • Golimumab
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy : final results of the randomized GO-FORTH trial. / Tanaka, Yoshiya; Harigai, Masayoshi; Takeuchi, Tsutomu; Yamanaka, Hisashi; Ishiguro, Naoki; Yamamoto, Kazuhiko; Miyasaka, Nobuyuki; Koike, Takao; Baker, Daniel; Ishii, Yutaka; Yoshinari, Toru.

In: Modern Rheumatology, 22.12.2015, p. 1-10.

Research output: Contribution to journalArticle

@article{26bb7674aff84395859fa284e736a282,
title = "Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results of the randomized GO-FORTH trial",
abstract = "Objective: To evaluate the safety and efficacy of golimumab + methotrexate (MTX) in Japanese patients with active rheumatoid arthritis (RA). Methods: Japanese patients with active RA despite MTX were randomized to placebo + MTX (Group 1, n = 88), golimumab 50 mg + MTX (Group 2, n = 86), or golimumab 100 mg + MTX (Group 3, n = 87). Patients with ",
keywords = "Anti-tumor necrosis factor, Asian, Golimumab, Rheumatoid arthritis",
author = "Yoshiya Tanaka and Masayoshi Harigai and Tsutomu Takeuchi and Hisashi Yamanaka and Naoki Ishiguro and Kazuhiko Yamamoto and Nobuyuki Miyasaka and Takao Koike and Daniel Baker and Yutaka Ishii and Toru Yoshinari",
year = "2015",
month = "12",
day = "22",
doi = "10.3109/14397595.2015.1109762",
language = "English",
pages = "1--10",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",

}

TY - JOUR

T1 - Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy

T2 - final results of the randomized GO-FORTH trial

AU - Tanaka, Yoshiya

AU - Harigai, Masayoshi

AU - Takeuchi, Tsutomu

AU - Yamanaka, Hisashi

AU - Ishiguro, Naoki

AU - Yamamoto, Kazuhiko

AU - Miyasaka, Nobuyuki

AU - Koike, Takao

AU - Baker, Daniel

AU - Ishii, Yutaka

AU - Yoshinari, Toru

PY - 2015/12/22

Y1 - 2015/12/22

N2 - Objective: To evaluate the safety and efficacy of golimumab + methotrexate (MTX) in Japanese patients with active rheumatoid arthritis (RA). Methods: Japanese patients with active RA despite MTX were randomized to placebo + MTX (Group 1, n = 88), golimumab 50 mg + MTX (Group 2, n = 86), or golimumab 100 mg + MTX (Group 3, n = 87). Patients with 

AB - Objective: To evaluate the safety and efficacy of golimumab + methotrexate (MTX) in Japanese patients with active rheumatoid arthritis (RA). Methods: Japanese patients with active RA despite MTX were randomized to placebo + MTX (Group 1, n = 88), golimumab 50 mg + MTX (Group 2, n = 86), or golimumab 100 mg + MTX (Group 3, n = 87). Patients with 

KW - Anti-tumor necrosis factor

KW - Asian

KW - Golimumab

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=84951286280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951286280&partnerID=8YFLogxK

U2 - 10.3109/14397595.2015.1109762

DO - 10.3109/14397595.2015.1109762

M3 - Article

SP - 1

EP - 10

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

ER -